Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most safety-related claims are not supported by the provided prescribing information excerpts, which do not include specific frequencies for GI adverse reactions or statements about the GI side-effect mechanism. Some liver/pancreatitis and microbiome mechanism claims cannot be validated from the supplied label text.
Category Scores
Accurate Statements
Unsupported Statements
Darolutamide can cause diarrhea in up to 34% of patients.
The provided label excerpt for adverse reactions does not state diarrhea incidence or any GI reaction frequency figures.
Darolutamide can cause nausea in around 25% of patients.
The provided label excerpt does not provide nausea incidence or frequency.
Darolutamide can cause abdominal pain in up to 20% of patients.
The provided label excerpt does not provide abdominal pain incidence or frequency.
Darolutamide can cause constipation in around 15% of patients.
The provided label excerpt does not provide constipation incidence or frequency.
Darolutamide can cause vomiting in up to 10% of patients.
The provided label excerpt does not provide vomiting incidence or frequency.
Darolutamide can cause gastroesophageal reflux disease (GERD) in some patients.
The provided label excerpt does not mention GERD as an adverse reaction.
Darolutamide can cause pancreatitis rarely.
The provided label excerpt does not mention pancreatitis.
Darolutamide can cause hepatic enzyme elevations.
While the label excerpt notes increased AST and increased ALT, it does not support the broader phrasing 'hepatic enzyme elevations' as a specific claim with implied frequency; additionally, no frequency is provided for this statement.
Darolutamide can cause hepatic failure in rare cases.
The provided label excerpt does not mention hepatic failure.
The exact cause of darolutamide gastrointestinal side effects is not fully understood.
No mechanism/causality statement for GI adverse reactions is provided in the supplied label excerpts.
Darolutamide is thought to cause gastrointestinal side effects by causing changes in the gut microbiome.
No microbiome mechanism is provided in the supplied label excerpts.
Contradictions
Important Omissions
No label-supported linkage of the specific GI adverse reaction frequencies (34%, 25%, 20%, 15%, 10%) to NUBEQA is present in the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response asserts multiple GI adverse reaction types with specific (but label-unverified) frequencies and includes unverified serious GI/hepatic events and a microbiome mechanism. Because these details are not supported by the provided label text, the reliability of the safety characterization is poor.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple adverse reaction claims (GI symptoms with specific percentages, GERD, pancreatitis, hepatic failure) and mechanistic statements are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to adverse reaction information explicitly present in the provided label excerpt (e.g., 'increased AST'/'increased ALT', 'fatigue', etc.) and remove or qualify any GI symptom frequency figures or mechanistic/microbiome explanations unless they are shown in the supplied prescribing information.